GLP-2 (HUMAN) manufacturers
- GLP-2 (HUMAN)
-
- $7.00 / 1KG
-
2020-02-19
- CAS: 99120-49-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100kg
|
| | GLP-2 (HUMAN) Basic information |
| Product Name: | GLP-2 (HUMAN) | | Synonyms: | HIS-ALA-ASP-GLY-SER-PHE-SER-ASP-GLU-MET-ASN-THR-ILE-LEU-ASP-ASN-LEU-ALA-ALA-ARG-ASP-PHE-ILE-ASN-TRP-LEU-ILE-GLN-THR-LYS-ILE-THR-ASP-ARG;Glucagon-Like Peptide II, (1-34), human;HIS-ALA-ASP-GLY-SER-PHE-SER-ASP-GLU-MET-ASN-THR-ILE-LEU-ASP-ASN-LEU-ALA-ALA-ARG-ASP-PHE-ILE-ASN-TRP-LEU-ILE-GLN-THR-LYS-ILE-THR-ASP-ARG: HADGSFSDEMNTILDNLAARDFINWLINTKITDR;GLP-2 (1-34) (huMan)
Proglucagon (126-159) (huMan), Preproglucagon (146-179) (huMan), Glucagon-Like Peptide 2-Arg (huMan);Proglucagon (126-159) (huMan), Preproglucagon (146-179) (huMan), Glucagon-Like Peptide 2-Arg (huMan);GLP-2 (1-34) (HUMAN);GLP-2-Arg, Preproglucagon 126-159;Preproglucagon 126-159 | | CAS: | 99120-49-7 | | MF: | C171H266N48O56S1 | | MW: | 3922.29 | | EINECS: | | | Product Categories: | Peptide | | Mol File: | Mol File | ![GLP-2 (HUMAN) Structure]() |
| | GLP-2 (HUMAN) Chemical Properties |
| storage temp. | −20°C | | form | solid |
| | GLP-2 (HUMAN) Usage And Synthesis |
| Uses | Glucagon-Like Peptide 2 (GLP-2) -Arg human trifluoroacetate salt has been used for injection in chickens to determine the effects of GLP-2 on the weight and morphology of small intestines. | | General Description | Glucagon-like peptide 2 (GLP-2) is a member of the pro-glucagon gene family which is released in small and large intestinal circulation by enteroendocrine L cells. This peptide is composed of 33 amino acids. | | Biochem/physiol Actions | Glucagon-like peptide 2 (GLP-2) influences the functionality of gastrointestinal tract by participating in the feedback loop to the brain for the control of food intake. It also controls digestion and absorption, and has tropic effects post chemotherapy injury or surgical resection. This peptide is also responsible for epithelial cell proliferation of the small bowel. Studies in rats show that this peptide enhances the effects of the ileal-brake hormones, GLP-1 and peptide YY. It also negatively regulates gastrointestinal motility and secretion. Thus, it has potential as a therapeutic agent in short-bowel syndrome. |
| | GLP-2 (HUMAN) Preparation Products And Raw materials |
|